Results 111 to 120 of about 26,025 (223)

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Nature Communications, 2019
The BCL-2 mutation G101V reduces venetoclax affinity and confers drug resistance in patients with chronic lymphocytic leukaemia. Here, the authors present crystal structures and biochemical analyses of venetoclax bound to BCL-2 and the G101V mutant ...
Richard W. Birkinshaw, Jia-nan Gong, Cindy S. Luo, Daisy Lio, Christine A. White, Mary Ann Anderson, Piers Blombery, Guillaume Lessene, Ian J. Majewski, Rachel Thijssen, Andrew W. Roberts, David C. S. Huang, Peter M. Colman, Peter E. Czabotar   +13 more
doaj   +1 more source

Treatment Outcomes and Overall Survival of Patients With B‐Cell Prolymphocytic Leukemia

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction B‐cell prolymphocytic leukemia (B‐PLL) is a rare, aggressive leukemic B‐cell malignancy historically associated with poor outcomes and recently reclassified in the WHO Fifth Edition but retained as a distinct entity in the ICC.
Daniel A. Ermann, Victoria A. Vardell, Lindsey Fitzgerald, Allison Bock, Harsh Shah, Boyu Hu, Deborah M. Stephens   +6 more
wiley   +1 more source

Na⁺/H⁺ Exchanger 1 Inhibition Overcomes Venetoclax Resistance in Acute Myeloid Leukemia

Cells
Despite advances with novel targeted agents (e.g., BCL-2 or IDH inhibitors) combined with chemotherapy for acute myeloid leukemia (AML), drug resistance persists.
Shin Young Hyun, Eun Jung Na, Yu Ri Kim, Yoo Hong Min, June-Won Cheong   +4 more
doaj   +1 more source

Precision Medicine in a Patient With Multiple Myeloma Presenting With t(2;11) and CCND1 Overexpression

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Translocations involving CCND1 are well described in multiple myeloma (MM), most frequently t(11;14), but rearrangements involving the immunoglobulin kappa (IGK) locus are rare. We present a case of a 71‐year‐old female with MM harboring t(2;11)(p11.2;q13), resulting in IGK::CCND1, with cyclin D1 and BCL‐2 overexpression.
Ariel Siegel, Chloe Ray, Meenakshi Mehrotra, Bruce Petersen, Sundar Jagannath, Samir Parekh, Jane Houldsworth, Hearn Jay Cho   +7 more
wiley   +1 more source

NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia

Journal of Translational Medicine
Background Acute myeloid leukaemia (AML) comprises a group of heterogeneous and aggressive haematological malignancies with unsatisfactory prognoses and limited treatment options.
Ying Lu, Xia Jiang, Youhong Li, Fenglin Li, Mengting Zhao, Ye Lin, Lili Jin, Haihui Zhuang, Shuangyue Li, Peipei Ye, Renzhi Pei, Jie Jin, Lei Jiang   +12 more
doaj   +1 more source

Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Objective To retrospectively analyze the early efficacy and safety of azacitidine plus lisaftoclax in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome with increased blasts (MDS‐IB), providing a reliable clinical reference.
Shan Meng, Wanhong Zhao, Hui Zhang, Bo Lei, Wanggang Zhang, Yilin Zhang, Jin Wang, Yinxia Chen, Xingmei Cao, Liufang Gu   +9 more
wiley   +1 more source

Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oxidative stress is involved in several key processes in cancer, including redox regulation, DNA damage, post‐translational modifications, transcriptional regulation, epigenetic modifications, metabolic reprogramming, cell death, and immune modulation. These mechanisms collectively influence tumor progression, immune evasion, and therapeutic responses,
Zhen Wang, Bowen Li, Pan Tang, Fanchen Yan, Shuxin Wang, Guiying Leng, Panduo Dawa, Yuansi Chen, Yihan Guo, Pan Yang, Yi Li, Siyu Liu, Erdan Dong, Siyuan Qin, Zhoufeng Wang   +14 more
wiley   +1 more source

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia

Cancer Medicine
Background ASXL1 is one of the most frequently mutated genes in acute myeloid leukemia (AML) and retains adverse‐risk status in intensively treated cohorts according to 2022 European Leukemia Net (ELN) risk criteria.
Yiming Cai, Jingwen Rui, Zhengwen Ding, Judan Xie, Zhou Jin, Jinyan Xiao, Yang Xu   +6 more
doaj   +1 more source

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report

Reports
Background and Clinical Significance: Tumor lysis syndrome (TLS) is a rare occurrence in patients treated with venetoclax mono- or combination therapy, and clear protocols guiding TLS prophylaxis are lacking.
Reilly Fankhauser, Alan Lu, Adetola Kassim, Eden Biltibo   +3 more
doaj   +1 more source